2026年11月5日星期四
M
Chroniques universelles
Flash info mondial
Japan's scandal-hit Nidec to have $3.8bn in credit lines renewed— 日经 Nikkei AsiaJapan wants US tech companies to share undisclosed software flaws as risks mount— 日经 Nikkei AsiaJapan's trading house chiefs warn of uncertainty after US midterms— 日经 Nikkei AsiaIndonesia chief of staff sacked for allegedly wiretapping President Prabowo— 日经 Nikkei AsiaTencent says its Hy4 joins 'top-tier' of open-source AI models— 日经 Nikkei AsiaAsian stocks face volatility as Democratic blue wave sweeps US— 日经 Nikkei AsiaChina's slumping state airlines pin hopes on overseas demand like exporters— 日经 Nikkei AsiaDemocrats win control of Congress in sharp rebuke to Trump— 日经 Nikkei AsiaJapan's scandal-hit Nidec to have $3.8bn in credit lines renewed— 日经 Nikkei AsiaJapan wants US tech companies to share undisclosed software flaws as risks mount— 日经 Nikkei AsiaJapan's trading house chiefs warn of uncertainty after US midterms— 日经 Nikkei AsiaIndonesia chief of staff sacked for allegedly wiretapping President Prabowo— 日经 Nikkei AsiaTencent says its Hy4 joins 'top-tier' of open-source AI models— 日经 Nikkei AsiaAsian stocks face volatility as Democratic blue wave sweeps US— 日经 Nikkei AsiaChina's slumping state airlines pin hopes on overseas demand like exporters— 日经 Nikkei AsiaDemocrats win control of Congress in sharp rebuke to Trump— 日经 Nikkei Asia

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial

Source Nature 生命科学il y a 1 jours
Résumé du contenu

Ce site ne fournit qu'un index de titres et de résumés ; le contenu complet et les droits d'auteur appartiennent à l'éditeur d'origine. Veuillez cliquer sur le lien original pour lire.

Aller à l'article original
Chaîne d'appartenance
Science
Région d'appartenance
Perspective mondiale
Langue de l'original
English
Numéro d'entrée
science-f81c0280

Comments 0 comments

No comments yet. Be the first.

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial · Chroniques universelles